<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00068757</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-16023-10051</org_study_id>
    <secondary_id>EORTC-16023-10051</secondary_id>
    <secondary_id>SPRI-P01900</secondary_id>
    <nct_id>NCT00068757</nct_id>
  </id_info>
  <brief_title>Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer</brief_title>
  <official_title>Phase I Study of Lonafarnib (SCH66336) in Combination With Herceptin Plus Paclitaxel in HER 2 NEU Overexpressing Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die. Lonafarnib may stop the growth of&#xD;
      tumor cells by blocking the enzymes necessary for their growth. Monoclonal antibodies, such&#xD;
      as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing&#xD;
      substances to them without harming normal cells. Combining lonafarnib and trastuzumab with&#xD;
      paclitaxel may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of lonafarnib when&#xD;
      given together with trastuzumab and paclitaxel in treating patients with&#xD;
      HER2/neu-overexpressing stage IIIB, stage IIIC, or stage IV breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose and recommended phase II dose of lonafarnib in&#xD;
           combination with trastuzumab (Herceptin®) and paclitaxel in patients with&#xD;
           HER2/neu-overexpressing stage IIIB, IIIC, or IV breast cancer.&#xD;
&#xD;
        -  Determine the qualitative and quantitative toxicity of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the pharmacokinetic profiles of these drugs in these patients.&#xD;
&#xD;
        -  Correlate the pharmacodynamics with the pharmacokinetics of this regimen in these&#xD;
           patients.&#xD;
&#xD;
        -  Correlate the pharmacokinetics and pharmacodynamics of this regimen with observed&#xD;
           toxicity in these patients.&#xD;
&#xD;
        -  Determine the response to this regimen in patients with measurable disease.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, open-label, multicenter, dose-escalation study of&#xD;
      lonafarnib.&#xD;
&#xD;
        -  Course 1: Patients receive a loading dose of trastuzumab (Herceptin®) IV over 90 minutes&#xD;
           on day 1 and over 30 minutes on days 8 and 15. Patients also receive paclitaxel IV over&#xD;
           3 hours on day 1.&#xD;
&#xD;
        -  Course 2: Patients receive trastuzumab IV over 30 minutes on days 1, 8, and 15 and&#xD;
           paclitaxel IV over 3 hours on day 2. Patients also receive oral lonafarnib twice daily&#xD;
           on days 3-21.&#xD;
&#xD;
        -  Course 3 and all subsequent courses: Patients receive oral lonafarnib twice daily on&#xD;
           days 1-21; trastuzumab IV over 30 minutes on days 1, 8, and 15; and paclitaxel IV over 3&#xD;
           hours on day 1.&#xD;
&#xD;
      Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of lonafarnib until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed every 8 weeks until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-36 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity and maximum tolerated dose as measured by CTC v 2.0</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Translational research</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) and pharmacodynamics (PD)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response as measured by RECIST criteria</measure>
  </secondary_outcome>
  <enrollment type="Actual">23</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lonafarnib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed breast cancer&#xD;
&#xD;
               -  Stage IIIB, IIIC, or IV&#xD;
&#xD;
          -  HER2/neu overexpression&#xD;
&#xD;
               -  3+ by immunohistochemistry&#xD;
&#xD;
                    -  2+ allowed if positive fluorescent in situ hybridization&#xD;
&#xD;
          -  Disease meets the following treatment criteria:&#xD;
&#xD;
               -  Paclitaxel/trastuzumab (Herceptin®) may be appropriate therapy&#xD;
&#xD;
               -  Anthracycline therapy is not a suitable approach&#xD;
&#xD;
          -  No clinical signs of CNS involvement&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10.0 g/dL (6.2 mmol/L)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase less than 2.5 times ULN (5 times ULN if liver metastases are&#xD;
             present)&#xD;
&#xD;
          -  AST and ALT less than 2.5 times ULN (5 times ULN if liver metastases are present)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance at least 40 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Cardiac ejection fraction normal by MUGA&#xD;
&#xD;
          -  QTc interval no greater than 440 msec&#xD;
&#xD;
          -  No cardiac dysfunction&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for up to 3 months after&#xD;
             study participation&#xD;
&#xD;
          -  No concurrent severe/unstable systemic disease&#xD;
&#xD;
          -  No infection&#xD;
&#xD;
          -  No circumstances that would preclude study participation (e.g., alcoholism or&#xD;
             substance abuse)&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study compliance and follow-up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 1 year since prior trastuzumab&#xD;
&#xD;
          -  No concurrent prophylactic growth factors&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 1 year since prior paclitaxel&#xD;
&#xD;
          -  More than 4 weeks since other prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 1 day since prior hormonal therapy&#xD;
&#xD;
          -  More than 2 days since prior high-dose chronic steroids&#xD;
&#xD;
          -  More than 2 days since prior ethinyl estradiol&#xD;
&#xD;
          -  No concurrent high-dose chronic steroids&#xD;
&#xD;
          -  No concurrent ethinyl estradiol&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 2 days since prior administration of and no concurrent CYP3A4 inducers or&#xD;
             inhibitors, including any of the following:&#xD;
&#xD;
               -  Gestodene&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Cimetidine&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Sulfinpyrazone&#xD;
&#xD;
          -  No concurrent grapefruit juice&#xD;
&#xD;
          -  No other concurrent anticancer agents&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan H. M. Schellens, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie Hopital</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>September 10, 2003</study_first_submitted>
  <study_first_submitted_qc>September 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2003</study_first_posted>
  <last_update_submitted>September 11, 2012</last_update_submitted>
  <last_update_submitted_qc>September 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <keyword>HER2-positive breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Lonafarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

